Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer | NEJM
Outcomes in patients with hormone receptor–positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy in patients with me…